PHIO PHARMACEUTICALS CORP. Stock Issued During Period, Value, Acquisitions
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- PHIO PHARMACEUTICALS CORP. stock issued during period, value, acquisitions for the quarter ending 2013-12-31 was $0.00.
- PHIO PHARMACEUTICALS CORP. stock issued during period, value, acquisitions for the quarter ending 2013-09-30 was $0.00.
- PHIO PHARMACEUTICALS CORP. stock issued during period, value, acquisitions for the quarter ending 2013-06-30 was $0.00.
- PHIO PHARMACEUTICALS CORP. stock issued during period, value, acquisitions for the quarter ending 2013-03-31 was $12.25M.
- PHIO PHARMACEUTICALS CORP. stock issued during period, value, acquisitions for fiscal 2013 was $12.25M, a 98.44% increase from fiscal 2012.
- PHIO PHARMACEUTICALS CORP. stock issued during period, value, acquisitions for fiscal 2012 was $6.17M.
| Period end | Stock Issued During Period, Value, Acquisitions 3 month | Stock Issued During Period, Value, Acquisitions 12 month |
|---|---|---|
| 2013-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-30 | $12.25M 10-K · filed 2015-03-30 |
| 2013-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-14 | |
| 2013-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-14 | |
| 2013-03-31 | $12.25M 10-Q · filed 2013-11-14 | |
| 2012-12-31 | $6.17M 10-K · filed 2014-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |